scholarly journals Use of Alum-Treated Pertussis Vaccine, and of Alum-Precipitated Combined Pertussis Vaccine and Diphtheria Toxoid, for Active Immunization

1942 ◽  
Vol 32 (6) ◽  
pp. 615-626 ◽  
Author(s):  
Pearl L. Kendrick
Keyword(s):  
Pertussis Vaccine ◽  
Active Immunization ◽  
Diphtheria Toxoid

scholarly journals Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents

2018 ◽  
Vol 27 (8) ◽  
pp. 921-925 ◽  
Author(s):  
Michael L. Jackson ◽  
Onchee Yu ◽  
Jennifer C. Nelson ◽  
James D. Nordin ◽  
Sara Y. Tartof ◽  
...  
Keyword(s):  
Pertussis Vaccine ◽  
Tetanus Toxoid ◽  
Acellular Pertussis Vaccine ◽  
Diphtheria Toxoid ◽  
Repeated Doses

Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine

Vaccine ◽  
2016 ◽  
Vol 34 (22) ◽  
pp. 2496-2500 ◽  
Author(s):  
Andrew Terranella ◽  
Vicki Rea ◽  
Matthew Griffith ◽  
Susan Manning ◽  
Steven Sears ◽  
...  
Keyword(s):  
Pertussis Vaccine ◽  
Tetanus Toxoid ◽  
Vaccine Effectiveness ◽  
Acellular Pertussis Vaccine ◽  
Diphtheria Toxoid

Comparison of a Three-Component Acellular Pertussis Vaccine With a Whole-Cell Pertussis Vaccine in 15- Through 20-Month-Old Infants

PEDIATRICS ◽  
1994 ◽  
Vol 93 (4) ◽  
pp. 656-659
Author(s):  
Henry H. Bernstein ◽  
Edward P. Rothstein ◽  
Sarah S. Long ◽  
Keith S. Reisinger ◽  
Mark M. Blatter ◽  
...  
Keyword(s):  
Immune Responses ◽  
Pertussis Vaccine ◽  
Tetanus Toxoid ◽  
Geometric Mean ◽  
Acellular Pertussis Vaccine ◽  
Diphtheria Toxoid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Double Blind ◽  
Whole Cell ◽  
Filamentous Hemagglutinin

Objective. To compare the immunogenicity and reactogenicity of a diphtheria and tetanus toxoids and three-component acellular pertussis vaccine (DTaP) with a diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTwP) when administered as a booster dose to infants 15 through 20 months of age. Design. Randomized, double-blind, comparative study. Setting. Three pediatric practices (two private; one hospital-based). Participants. One hundred and sixty-five healthy 15-through 20-month old infants. Selection procedures and interventions. Infants were randomly assigned in a 2:1 ratio to receive vaccine from a single lot of DTaP or from commercially available DTwP. DTaP contained 25 µg of pertussis toxoid, 25 µg of filamentous hemagglutinin, 8 µg of pertactin (69-kilodalton outer membrane protein), 25 flocculating units of diphtheria toxoid, and 10 flocculating units of tetanus toxoid per 0.5-mL dose. DTwP contained one half the concentrations of diphtheria and tetanus toxoids compared with DTaP and a pertussis component with a potency of 4 U/0.5-mL dose. Serum samples were obtained on the day of immunization and 4 weeks later. Adverse reactions were recorded by parents for 7 days after immunization. An interval history was obtained 4 weeks after immunization. Measurements and results. IgG antibody to pertussis toxoid, filamentous hemagglutinin, pertactin, diphtheria toxoid, and tetanus toxoid was measured by an indirect enzyme-linked immunosorbent assay (ELISA) method. One month after immunization, the geometric mean antibody levels after DTaP compared with DTwP were: pertussis toxoid, 70.6 vs 28 ELISA U/mL (P = .003); filamentous hemagglutinin, 183.4 vs 43 ELISA U/mL (P < .001); pertactin, 216 vs 49.9 ELISA U/mL (P < .001); diphtheria, 14.1 vs 14.9 IU/mL (P = .74); and tetanus, 11.9 vs 14.8 IU/mL (P = .089). After immunization with DTaP, most local and systemic adverse experiences were significantly fewer compared with DTwP (P < .05). Conclusions. This three-component DTaP vaccine demonstrates significantly greater immune responses to pertussis toxoid, filamentous hemagglutinin, and pertactin, equivalent immune responses to diphtheria and tetanus toxoids, and significantly less reactogenicity compared with a licensed DTwP.

Sign in / Sign up

Export Citation Format

Share Document